Higher hepatic gene expression and serum levels of matrix metalloproteinase-2 are associated with steatohepatitis in non-alcoholic fatty liver diseases

Biomarkers

Volumn 18, Issue 1, 2013, Pages 82-87

  Toyoda, Hidenori ^a   Kumada, Takashi ^a   Kiriyama, Seiki ^a   Tanikawa, Makoto ^a   Hisanaga, Yasuhiro ^a   Kanamori, Akira ^a   Tada, Toshifumi ^a   Murakami, Yoshiki ^b  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gene expression; Hyaluronic acid; Matrix metalloproteinases; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Serum levels; Tissue inhibitors of metalloproteinases

Indexed keywords

COLLAGENASE 3; GELATINASE A; HYALURONIC ACID; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LIVER; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MATRIX METALLOPROTEINASE 2 GENE; NONALCOHOLIC FATTY LIVER;

AGED; FATTY LIVER; FEMALE; HUMANS; HYALURONIC ACID; LIVER; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84872543846     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.738249     Document Type: Article

References (16)

1. Adams LA. (2011). Biomarkers of liver fibrosis. J Gastroenterol Hepatol 26:802-809.
2. Angulo P. (2002). Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231.
3. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. (1999). Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467-2474.
4. Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD; Asia-Pacific Working Party on NAFLD. (2007). Non-alcoholic fatty liver disease in the Asia-Pacific region: Definitions and overview of proposed guidelines. J Gastroenterol Hepatol 22:778-787.
5. Clark JM, Brancati FL, Diehl AM. (2003). The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98:960-967.
6. Ebata M, Fukuda Y, Nakano I, Katano Y, Fujimoto N, Hayakawa T. (1997). Serum levels of tissue inhibitor of metalloproteinases-2 and of precursor form of matrix metalloproteinase-2 in patients with liver disease. Liver 17:293-299.
7. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. (2004). Natural history of nonalcoholic steatohepatitis: A longitudinal study of repeat liver biopsies. Hepatology 40:820-826.
8. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T. (2007). The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 102:2708-2715.
9. Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M, Tokushige K, Shiratori K. (2005). The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 33:72-76.
10. Hemmann S, Graf J, Roderfeld M, Roeb E. (2007). Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 46:955-975.
11. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. (2003). Increase in the prevalence of fatty liver in Japan over the past 12 years: Analysis of clinical background. J Gastroenterol 38:954-961.
12. Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, Byrnes V, Afdhal N. (2009). The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 24:564-568.
13. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. (1999). Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 116:1413-1419.
14. Miele L, Forgione A, La Torre G, Vero V, Cefalo C, Racco S, Vellone VG, Vecchio FM, Gasbarrini G, Rapaccini GL, Neuman MG, Grieco A. (2009). Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. Transl Res 154:194-201.
15. Musso G, Gambino R, Cassader M. (2010). Non-alcoholic fatty liver disease from pathogenesis to management: An update. Obes Rev 11:430-445.
16. Torres DM, Harrison SA. (2008). Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 134:1682-1698.